|
Molina-Lopez C, Hurtado-Navarro L, Garcia CJ, Angosto-Bazarra D, Vallejo F, Tapia-Abellan A, Marques-Soares JR, Vargas C, Bujan-Rivas S, Tomas-Barberan FA, Arostegui JI, Pelegrin P. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1beta production. Nat Commun. 2024 Feb 6;15(1):1096. doi: 10.1038/s41467-024-44990-0. PubMed PMID: 38321014; PubMed Central PMCID: PMC10847128.
AÑO: 2024; IF: 14.7
|
38321014
|
Martin-Sanchez F, Penin-Franch A, Angosto-Bazarra D, Tapia-Abellan A, Compan V, Pelegrin P. Measuring NLR Oligomerization III: Detection of NLRP3 and NLRC4 Complex by Bioluminescence Resonance Energy Transfer. Methods Mol Biol. 2023;2696:93-103. doi: 10.1007/978-1-0716-3350-2_6. PubMed PMID: 37578717.
AÑO: 2023
|
|
Weber ANR, Tapia-Abellan A, Liu X, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply. Rheumatology (Oxford). 2023 May 2;62(5):e168-e169. doi: 10.1093/rheumatology/keac718. No abstract available. PubMed PMID: 36562561.
AÑO: 2023; IF: 4.7
|
|
Martin-Sanchez F, Compan V, Penin-Franch A, Tapia-Abellan A, Gomez AI, Banos-Gregori MC, Schmidt FI, Pelegrin P. ASC oligomer favors caspase-1CARD domain recruitment after intracellular potassium efflux. J Cell Biol. 2023 Aug 7;222(8):e202003053. doi: 10.1083/jcb.202003053. Epub 2023 Jul 4. PubMed PMID: 37402211; PubMed Central PMCID: PMC10318405.
AÑO: 2023; IF: 7.4
|
|
Weber ANR, Tapia-Abellan A, Liu X, Dickhofer S, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. Rheumatology (Oxford). 2022 Oct 6;61(10):e299-e313. doi: 10.1093/rheumatology/keac273. No abstract available. PubMed PMID: 35579347.
AÑO: 2022; IF: 5.5
|